Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Califf On Real World Evidence: 'Use It For The Right Purposes'

This article was originally published in The Pink Sheet Daily

Executive Summary

Commissioner champions data from randomized clinical practice studies to support benefit/risk decisions but also sees value in other types of data generated outside the traditional clinical trial setting.


Related Content

Gottlieb: If Trials Show 'More Certain Benefit,' Risk Can Be Considered Long-Term
FDA Chief Scientist Post A Chance For Califf To Make Mark
PDUFA's 'Real-World' Journey Expected To Be Slow Walk
Diabetes Drug Safety Might Be Best Assessed With Real-World Data
Clinical Trial Endpoints May Not Fit Real-World Studies
Real-World Evidence May Find A Home On Breakthrough Pathway
New Trial Designs Needed To Get Most Out Of CER, Duke's Califf Says





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts